Literature DB >> 22234410

Antimicrobial prenylated acetophenones from berries of Harrisonia abyssinica.

Regina K Mayaka1, Moses K Langat, Josiah O Omolo, Peter K Cheplogoi.   

Abstract

The ripe berries of Harrisonia abyssinica yielded two new prenylated acetophenones, namely 5-(ethan-1'''-one)-4,6-dihydroxy-7-(3'',3''-dimethylallyl)-2 S-(1' S-hydroxy-1',5'-dimethylhex-4'-enyl)-2,3-dihydrobenzofuran (1) and 5-(2'''-hydroxyethan-1'''-one)-4,6-dihydroxy-7-(3'',3''-dimethylallyl)-2 S-(1' S-hydroxy-1',5'-dimethylhex-4'-enyl)-2,3-dihydrobenzofuran (2), herein named harronin I and harronin II, respectively. The compounds were isolated following activity guided fractionation and the structures were determined using 1D, 2D NMR spectroscopic, CD and MS spectrometric techniques. The methanol-dichloromethane mixture (1 : 1 v/v) crude extract exhibited strong antimicrobial activity against Candida albicans, Bacillus cereus, Escherichia coli, Salmonella typhimurium, Staphylococcus aureus, and Lactobacillus casei. Harronin I (1) showed a MIC of 5 µg/mL against C. albicans, 6 µg/mL against B. cereus, and more than 20 µg/mL against other tested microorganisms. Harronin II (2) showed much weaker MIC values (> 100 µg/mL) against all the tested microorganisms. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234410     DOI: 10.1055/s-0031-1298143

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  2 in total

1.  Discovery of acylphloroglucinol-based meroterpenoid enantiomers as KSHV inhibitors from Hypericum japonicum.

Authors:  Linzhen Hu; Yanfei Liu; Yanxing Wang; Zhenzhen Wang; Jinfeng Huang; Yongbo Xue; Junjun Liu; Zhenming Liu; Yong Chen; Yonghui Zhang
Journal:  RSC Adv       Date:  2018-07-02       Impact factor: 4.036

Review 2.  A Systematic Review of Medicinal Plants of Kenya used in the Management of Bacterial Infections.

Authors:  Elizabeth A Odongo; Peggoty C Mutai; Beatrice K Amugune; Nelly N Mungai
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-24       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.